Document is current
Any future updates will be listed below
-
Authors
Blachutzik, Florian https://orcid.org/0000-0002-7695-3663
Honton, Benjamin
Escaned, Javier
Hill, Jonathan M.
Werner, Nikos
Banning, Adrian P.
Lansky, Alexandra J.
Schlattner, Sophia
De Bruyne, Bernard
Di Mario, Carlo
Dörr, Oliver
Hamm, Christian
Nef, Holger M.
-
Funding
Funding for this research was provided by:
Shockwave Medical Inc., Santa Clara, CA, USA
Justus-Liebig-Universität Gießen
- License Information
-
More Information
Article History
Received: 2 July 2020
Accepted: 21 August 2020
First Online: 18 September 2020
Compliance with ethical standards
:
: Bernard De Bruyne reports that The Cardiovascular Center Aalst receives grant support from Abbott Vascular, Boston Scientific, and Biotronik AG, and receives consulting fees on his behalf Abbott Vascular and Boston Scientific outside of the submitted work. Bernard De Bruyne is a shareholder for Siemens, GE, Bayer, Philips, HeartFlow, Edwards Life Sciences, and Ceyliad. Carlo Di Mario received an institutional research grant to the institution from Shockwave Medical for the DISRUPT CAD 2 trial. Christian Hamm is Advisory Board Member for Medtronic. Holger Nef received an Institutional Research Grant from Shockwave Medical as well as speaker honorary from Shockwave Medical. All other authors report no relevant conflicts of interest.
